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Background: Subanesthetic doses of ketamine, an N-methyl-d-aspartate receptor antagonist
used as an adjuvant to opioid for the treatment of pain in adults with acute and chronic pain,
have been shown, in some instances, to improve pain intensity and to decrease opioid intake.
However, less is known about the role of ketamine in pain management in children, adolescents,
and young adults.
Purpose: We examined the effects of subanesthetic ketamine on pain intensity and opioid
intake in children, adolescents, and young adults with acute and chronic pain syndromes treated
in an inpatient setting.
Methods: This is a longitudinal cohort study of patients treated with subanesthetic ketamine
infusions in regular patient care units in a tertiary pediatric hospital. Primary outcomes included
changes in pain scores and morphine-equivalent intake.
Results: The study cohort included 230 different patients who during 360 separate hospital
admissions received subanesthetic ketamine infusions for pain management. Overall, ketamine
infusions were associated with significant reductions in mean pain scores from baseline (mean
pain scores 6.64 [95% CI: 6.38–6.90]) to those recorded on the day after discontinuation of
ketamine (mean pain scores 4.38 [95% CI: 4.06–4.69]), p<0.001. Importantly, the effect of
ketamine on pain scores varied according to clinical diagnosis (p=0.011), infusion duration
(p=0.004), and pain location (p=0.004). Interestingly, greater reductions in pain scores were
observed in patients with cancer pain and patients with pain associated with pancreatitis and
Crohn’s disease. There were no records of psychotomimetic side effects requiring therapy.
Conclusion: These data suggest that administration of subanesthetic ketamine for pain management is feasible and safe in regular inpatient care units and may benefit children, adolescents,
and young adults with acute and chronic pain. This study is informative and can be helpful
in determining sample and effect sizes when planning clinical trials to determine the role of
subanesthetic ketamine infusions for pain management in pediatric patients.
Keywords: cancer pain, sickle cell disease, CRPS, postoperative pain, chronic pain, acute pain
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Ketamine has been used clinically since the 1960s as a general anesthetic.1 A decade
after its approval by the US Food and Drug Administration, researchers showed that ketamine reduces the excitatory response to N-methyl-d-aspartic acid (NMDA) in central
neurons, thus revealing its NMDA receptor antagonism properties2 and advancing our
understanding of the pharmacology of ketamine. Currently, clinicians use ketamine as
a general anesthetic less frequently, given its emergence psychotomimetic effects and
findings of neurotoxic effects shown in the developing brain of animals.3 Conversely,
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over the past decade, researchers have explored the effect of
subanesthetic doses of ketamine as an antidepressant4 and
as an analgesic.5,6
The use of subanesthetic ketamine as an analgesic is supported by evidence, from both animal and human studies,
implicating activation of NMDA receptors in the pathobiology of nociceptive, inflammatory, and neuropathic pain and
in central sensitization.7 In addition, activation of NMDA
receptors has also been shown in animals8 and in human
experimental studies9 to play a role in settings where acute or
chronic use of opioids is associated with tolerance or opioidinduced hyperalgesia. Therefore, based on these preclinical
findings, ketamine has been examined clinically as an adjuvant to opioids for the treatment of acute and chronic pain
and in settings of opioid-induced hyperalgesia.6,10 However,
among clinical studies, there has been a great variability in
ketamine doses and duration of administration. Additionally,
the beneficial effects of ketamine have not been consistently
reported, and some groups have been unable to show opioidsparing effects of ketamine in clinical settings associated with
opioid-induced hyperalgesia.11,12 Similarly, in chronic pain,
there are no definitive data supporting the use of ketamine
for the treatment of chronic regional pain syndrome (CRPS)
or other types of chronic pain.13 Further, in critical reviews of
available trials, researchers can only conclude that there might
be a beneficial role for ketamine as an adjuvant to opioids to
treat pain in the postoperative period, cancer pain, and chronic
pain.9,12,14,15 Consequently, as outlined in clinical guidelines,
the evidence to support the use of ketamine for the treatment
of acute and chronic pain is at best moderate.16,17
However, despite lack of conclusive clinical evidence to
support its use, clinicians from various disciplines in many
countries continue to use ketamine as an adjuvant to opioids
for acute and chronic pain management.18–21 Some argue that
in the setting of limited effective pharmacologic options,
one might be left with no alternative other than less studied
strategies such as ketamine infusions. Our institution has
used subanesthetic ketamine (defined as not >1 mg/kg/h)
to treat acute and chronic pain in children, adolescents, and
young adults since 2006. We have previously reported our
experience using ketamine for the treatment of cancer pain,
postoperative, and chronic pain.5,11 In this study, we sought to
examine the use of subanesthetic ketamine in a large number
of patients admitted to a tertiary pediatric hospital whose pain
proved unresponsive to routine pharmacologic interventions.
Specifically, we sought to determine the overall effect of
ketamine on pain scores and opioid intake, to identify factors
associated with larger or smaller effects and to examine the
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frequency with which ketamine was associated with clinically meaningful reductions in pain scores and opioid intake.

Methods
Data collection
The Children’s National Health System Institutional
Review Board approved this longitudinal cohort study
and a waiver for written informed consent in 2014
(Pro00004569). Requirement for patient written consent to
review their records was waived as this was a minimal risk
study and the data collected were devoid of patient identifiers. Patients who had received subanesthetic doses of
ketamine for pain management were eligible for inclusion
in this study. We reviewed a list of all patients (obtained
from the hospital pharmacy records) who were admitted
between January 2006 and April 2014 and had received
an order for continuous infusion of intravenous ketamine.
Patients who lacked a pain medicine consult, underwent a
spinal fusion procedure (those patients were part of a previously reported investigational study11), had incomplete
record of pain scores and/or opioid intake, or received
ketamine only for the purpose of sedation were excluded.
Data collected included sex, age, race, ketamine infusion
duration, pain duration (acute vs chronic), pain diagnoses
(vaso-occlusive episodes [VOE], visceral, CRPS, headache,
or other [mucositis, diabetic neuropathy, neurofibromatosis,
and postural orthostatic tachycardia syndrome]), primary
clinical diagnosis (accidental trauma, surgical trauma, and
postoperative pain [patients who had a planned surgical
procedure during hospitalization], functional gastrointestinal disorder [chronic and/or recurrent gastrointestinal
symptoms with no identified etiology], inflammatory disease [pancreatitis or Crohn’s disease], sickle cell disease,
malignancy, or other), and primary pain location. Patients
with pain in more than two locations were classified as having generalized pain. From the medical charts, we retrieved
documentation of hemodynamic changes that warranted
treatment with vasoactive agents, as well as reports of
psychotropic effects, nausea, vomiting, and changes in
sleep pattern. All pain scores recorded throughout admission days were collected. We then calculated average daily
pain scores before (day prior to ketamine administration)
and after (24 h, 48 h, and on the day after discontinuation)
ketamine infusion. Pain scores were measured using the
Numeric Rating Scale (NRS), the Wong-Baker FACES®, or
the Face, Legs, Activity, Cry, and Consolability (FLACC),
as appropriate. At the times indicated earlier, we also collected total daily opioid intake and then calculated the daily
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oral morphine-equivalent (per body weight in kilograms)
intake using the opioid conversion tool available at www.
globalrph.com/narcoticonv.htm.22
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Outcomes
The primary outcome was change in average pain scores
from baseline to postketamine infusion. Secondary outcomes included changes in oral morphine-equivalent intake
from baseline measurements to postketamine infusion and
proportion of ketamine infusions that resulted in clinically
meaningful reductions in pain scores and opioid intake.
We defined clinically meaningful change in pain scores or
opioid intake as a ≥20% reduction in pain scores and in
morphine-equivalent intake from baseline to the day after
ketamine discontinuation (day after ketamine - baseline/
baseline ¥100). Such a decline in pain score (20%) is larger
than the 12.5% decrease in pain score suggested by others
as being minimally clinically significant for adolescents with
chronic pain.23

Ketamine administration
At our institution, ketamine prescribed by the Pain Medicine
Division can be administered on regular inpatient care units
where oxygen delivery set-up, suction, and resuscitation
equipment are available. Trained nurses administer ketamine
infusions using a locked infusion pump and patients are
maintained on a cardiorespiratory monitor (heart and respiratory rate, blood pressure, and pulse oximeter). Criteria to
receive subanesthetic doses of ketamine infusions include
inadequate analgesia with standard pain therapy, opioid tolerance associated with undesirable side effects, opioid-induced
hyperalgesia, neuropathic pain, postoperative pain in patients
in whom opioid use was undesirable, or an opioid-sparing
effect was needed for clinical reasons. Ketamine infusions
used for end-of-life care were excluded. Exclusion criteria
for ketamine administration include history of psychosis,
intracranial hypertension, severe labile hypertension, or
poorly controlled cardiac arrhythmia, hypersensitivity to
ketamine, and age <3 months.
In our institution, ketamine infusions order sets are available, and the suggested starting doses are as follows: 1) for
opioid naive patients, ketamine is started at 0.05–0.4 mg/
kg/h; 2) for opioid tolerant patients (as documented by
the pain service), 0.05–1 mg/kg/h; and 3) for patients with
documented opioid-induced hyperalgesia, 1 mg/kg/h. During infusions, ketamine doses could be titrated according to
its indication and pain scores up to 1 mg/kg/h as allowed by
the Board of Nursing.

Journal of Pain Research 2017:10

Ketamine for pain management

Statistical analysis
The distributions of raw pain scores, daily opioid intake, and
changes over time were tested for normality. Because the
data were skewed, the Wilcoxon signed-rank test was used to
test for statistical significance of within-individuals changes
between baseline and posttreatment outcome measurements.
Box plots were used to examine how the individuallevel changes (between baseline and the day after ketamine
discontinuation) in raw pain scores and daily opioid intake
were distributed across the subgroups of the eight patient
characteristics (age, sex, race, duration of pain, clinical diagnosis, type of pain, location of pain, and duration of ketamine
infusion), and the distributions were tested for normality.
Because the data were skewed for certain characteristics,
nonparametric tests were used for all statistical analyses.
The Kruskal–Wallis test was used to compare the distribution of values across the subgroups of each patient
characteristic separately. When an overall difference was
detected, Dunn’s test (with a Bonferroni adjustment for
multiple comparisons) was then used to compare all possible
pairs of subgroups and identify any statistically significant
detectable differences.
The proportion of patients (95% confidence interval [CI])
who achieved clinically meaningful reductions in pain and
daily opioid intake were graphed in order to visually compare
how the proportions varied across the subgroups of all eight
patient characteristics.
Fisher’s exact test was used to examine whether the proportions varied across the subgroups of sex, race, duration
of pain, clinical diagnosis, type of pain, or location of pain.
A nonparametric test for trend was used to examine whether
the proportion of patients with a clinically meaningful reduction in pain scores and opioid intake systematically declined
across ordered age groups or by the duration of ketamine
infusion.
Stata 14.1/IC (StataCorp LLC, College Station, TX,
USA) was used to conduct all analyses. p-values <0.05 were
considered statistically significant except when Bonferroni’s
correction for multiple comparisons was applied. In those
instances, the statistically significant p-value was calculated
as 0.05/the total number of comparisons.

Results
Study cohort
We reviewed 1542 records, containing orders for subanesthetic ketamine administration (Figure 1). Records containing
ketamine orders not written by the Pain Medicine Division
were incomplete or were from patients who had undergone
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1101 records excluded
• Ketamine not ordered by
pain medicine
• Incomplete records
• Spinal fusion patients

Characteristic

251 patients received 441
infusions ordered by pain
medicine
57 infusions excluded:
• Missing pain scores or
morphine intake
24 infusions excluded:
• Repeated ketamine
infusions during one
admission
230 patients, 360 ketamine
infusions ordered by pain
medicine included in the analysis
Figure 1 Flowchart indicating patient selection and exclusion criteria.

spinal fusion (ketamine was administered as part of a
postoperative pain management and previously reported11)
were excluded. Two hundred and fifty-one patients and 441
infusions, which occurred between January 2006 and April
2014, met the study eligibility criteria. Of the 441 remaining
records, 57 were excluded as pain scores, and/or opioid intake
data were missing during the first or second day of ketamine
administration or for the 24 h after discontinuation of ketamine. Records from 24 ketamine infusions were eliminated
because they consisted of a second ketamine infusion during
a single hospital admission. The final study cohort included
data from 230 different patients who, during 360 separate
hospital admissions, received subanesthetic ketamine infusions for pain therapy. Of those, 180 patients were admitted
once, while the other 50 were each admitted between two
and ten times. For the purpose of this study, each admission
was considered an independent event.

Patients
Patient characteristics at the time of first ketamine infusion
are listed in Table 1. The median age was 14 years (interquartile range: 10–17 years). Over the 360 ketamine infusions,
most patients were from 12 to 18 years of age (58%), 6 to
11 years (17%), 19 to 21 years (14%), 3 to 5 years (5%),
>22 years (4%), and 1.1 to 2.9 years (3%). Most ketamine
infusions lasted 3 days (26%).
Seventy-eight percent of infusions (280) were administered to patients with acute pain and 22% to patients with
chronic pain. Additionally, most ketamine infusions (50%)
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Table 1 Characteristics of 230 patients who received 360
ketamine infusions while admitted to a pediatric hospitala

Sex
Female
Male
Age (years), median (25th–75th)
Race/ethnicity
African–American
Caucasian
Hispanic/Latino
Unknown
Ketamine infusions (360)
Sex
Female
Male
Race/ethnicity
African–American
Caucasian
Hispanic/Latino
Unknown
Duration (days)
Two
Three
Four
Five
Six or more

N (%)
106 (46)
124 (54)
14 (10–17)
131 (57)
70 (30)
13 (6)
16 (7)

203 (56)
157 (44)
229 (64)
94 (26)
15 (4)
22 (6)
49 (14)
93 (26)
76 (21)
52 (14)
90 (25)

Notes: aPatient’s characteristics are those at the time of first ketamine infusion.
Race/ethnicity was recorded from a patient self-reported file.

were administered to patients with sickle cell disease who had
been admitted for VOE, whereas 17% who had postoperative
pain after surgical trauma and 13% had malignancy-associated pain (Table 2). Pain locations are listed in Table 3. Most
patients had generalized pain (25%), followed by abdominal
(22%), lower extremity (21%), and chest (15%) pain.

Primary outcome
We collected average pain scores on the day prior to initiation of ketamine and on the first day of ketamine infusion.
In the hospital admissions (n=331 of 441) where both values
were originally available in the electronic medical record,
the average pain score on the day prior to ketamine initiation
(6.85 [95% CI: 6.58–7.11]) and on the first day of ketamine
infusion were similar (6.84 [95% CI: 6.59–7.08]), p=0.499.
Given that in all infusions, the average pain score values
were available on the first day of infusion, we considered
that as the baseline pain score for the final study cohort of
360 hospital admissions.
Overall, ketamine infusions were associated with significant reductions in average pain scores from the first day of
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Table 2 Clinical diagnosis for patients who received 360 infusions
of ketamine in an inpatient settinga
Associated diagnoses

n (%)

Sickle cell disease
Surgical trauma (postoperative pain)
Malignancy
Inflammatory diseases
Accidental trauma
Functional gastrointestinal disorder
Other

181 (50)
61 (17)
46 (13)
18 (5)
16 (4)
14 (4)
24 (7)

Notes: aClinical diagnoses were those recorded in the pain medicine consultation.
Inflammatory diseases included pancreatitis and Crohn’s disease. Other included
cystic fibrosis, diabetes mellitus, neurofibromatosis 1, postural orthostatic
tachycardia syndrome, and two cases simply coded as “other”.

Table 3 Pain location in 360 admissions where ketamine was
administered to treat pain in a tertiary care pediatric centera
Pain location

n (%)

Generalized
Abdomen
Lower extremity
Chest
Upper extremity
Back
Other

89 (25)
79 (22)
75 (21)
53 (15)
27 (8)
25 (7)
12 (3)

Note: aPain location was that recorded in the pain medicine consultation.

infusion (6.65 [95% CI: 6.39–6.91]) to the day after discontinuation of ketamine (4.38 [95% CI: 4.06–4.69]), p<0.001.
The effect of ketamine infusions on raw pain scores
(within-individual change) was similar comparing all age
groups (p=0.842), males and females (p=0.065), all races
(p=0.721), acute and chronic pain (p=0.460), and pain
types (p=0.894), data not shown. In contrast, the effect of
ketamine infusions on pain scores varied according to clinical diagnosis (p=0.01), infusion duration (p=0.004), and pain
location (p=0.004, Figure 2). Specifically, greater median
reductions in pain scores were observed in patients with
malignancy-associated pain and patients with inflammatory
disease (pancreatitis and Crohn’s disease), whereas the lowest were in patients with functional gastrointestinal disorder
and other (cystic fibrosis, diabetes mellitus, neurofribromatosis 1, postural orthostatic tachycardia syndrome, and two
cases simply coded as other, p=0.011 for overall difference,
Figure 2A). Regarding infusion durations, longer ketamine
infusions yielded greater median reductions in pain scores
(p=0.004, Figure 2B). Further, patients with back (-2.57
[-4.75, -1.56], median [25th, 75th percentiles respectively]),
abdominal (-1.91 [-3.88, -0.6]), and generalized (-1.87
[-3.43, -0.75]) pain had the greatest reductions, whereas
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patients with chest pain (-0.5 [-2.37, -0.33]) had the lowest
reductions in pain scores (p=0.004 for overall difference).

Secondary outcomes
Regarding opioid intake, ketamine infusions were associated
with significant decreases in overall average oral morphineequivalent intake from the first day of infusion (2.74 mg/kg/d
[2.47–3.00], mean [95% CI]) to the day after discontinuation
of ketamine (2.06 mg/kg/d [1.81–2.31]), p<0.001. There
was no impact of age, sex, race, pain duration (acute vs
chronic), or pain location or type on the effect of ketamine
on oral morphine-equivalent intake (all p≥0.322). However,
the ketamine effect on opioid intake varied according to
clinical diagnosis (p=0.030, Figure 2C) and duration of
infusion (p=0.022, Figure 2D). Specifically, greater median
reductions in opioid intake were observed in patients with
malignancy-associated pain and patients with sickle cell
disease, whereas lesser reductions were observed in patients
with accidental trauma and postoperative pain after surgical
trauma (p=0.030 for overall difference, Figure 2C). Regarding ketamine infusion duration, similar to the observation of
reduction in pain scores, longer ketamine infusions yielded
greater reductions in oral morphine-equivalent intake
(p=0.022, Figure 2D).
During ketamine administration, there were no records
of hallucinations, changes in sleep pattern, or hemodynamic
changes or arrhythmias requiring therapy in any patient.

Clinically meaningful reduction in pain
score and morphine-equivalent intake
We then examined the proportion of ketamine infusions
that yielded clinically meaningful changes in pain scores
and opioid intake, here defined as a ≥20% reduction in pain
scores and a ≥20% reduction in morphine-equivalent intake
after discontinuation of the infusion compared to baseline
levels, respectively. Overall, there was a ≥20% reduction in
pain scores in 58% of all ketamine infusions. The proportion
of infusions that yielded a 20% or greater reduction in pain
scores varied according to clinical diagnosis (p=0.003), pain
location (p=0.012), age (p=0.039), and duration of infusion
(p=0.017, Figure 3). For example, the highest proportion of
infusions associated with clinically meaningful reduction in
pain scores were observed among infusions administered to
cancer patients and patients with inflammatory diseases and
the lowest among patients with functional gastrointestinal
disorders (Figure 3A). There was a trend for higher frequency
of meaningful reduction in pains scores in males (63%) than
in females (54%), p=0.056. Conversely, the frequency of
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Pain score changes

Clinical diagnosis

Infusion duration (days)
4

2

2

0

0

–2

–2

–4

–4

–6

–6
p=0.011

C

p=0.004

–8
D

4

4

2

2

0

0

–2

–2

–4

–4

–6

–6
p=0.030

–8

CA IFD SCD POP AT FGID Other

p=0.022

–8
Two

Three

Four

Five ≥Six

Figure 2 Differential effect of ketamine on pain scores and opioid intake.
Notes: The box plots show median and 25th and 75th percentiles, and the whiskers 10th and 90th percentiles. (A) Box plots of the changes in pain scores from baseline to
the day after ketamine discontinuation according to primary clinical diagnosis. Ketamine infusions yielded greater reductions in pain scores in patients with cancer-associated
pain and patients with IFD (including pancreatitis and Crohn’s disease) and the lowest in patients with FGID and other (cystic fibrosis, diabetes mellitus, neurofibromatosis 1,
and postural orthostatic tachycardia syndrome), overall difference, p=0.011. (B) Effect of ketamine infusions on pain scores also varied according to the duration of ketamine
infusion as longer ketamine infusions yielded greater reductions in pain scores (p=0.004). (C) The ketamine effect on opioid intake also varied according to clinical diagnosis
(p=0.030) as greater reductions in opioid intake were observed in patients with cancer pain and patients with sickle cell disease, whereas lesser reductions were observed
in patients with accidental trauma and postoperative pain due to surgical trauma (p=0.030). (D) Similar to the observation for pain scores, longer ketamine infusions yielded
greater reductions in oral morphine-equivalent intake (p=0.022).
Abbreviations: CA, cancer; IFD, inflammatory disease; SCD, sickle cell disease; POP, postoperative pain; AT, accidental trauma; FGID, functional gastrointestinal disease.

meaningful reduction in pain scores did not vary with the type
(p=0.391) and duration of pain (p=0.224) or race (p=0.268).
Regarding the frequency of a meaningful reduction in
opioid intake, in 52% of ketamine infusions there were 20%
or greater reductions in opioid intake. The frequency of
infusions associated with ≥20% reduction in opioid intake
varied according to duration of ketamine infusion (p=0.030),
with longer durations infusions being more likely to result
in a meaningful reduction in opioid intake (data not shown).
Conversely, the frequency of a meaningful reduction in opioid
intake did not vary with the clinical diagnosis, type of pain,
duration of pain, location of pain, age, sex, or race.

Discussion
In this cohort study involving a large number of children,
adolescents, and young adults, we examined the effects of
subanesthetic ketamine infusions on pain intensity and opioid
intake. We found that continuous subanesthetic ketamine
infusions administered to children, adolescents, and young
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adults with inadequate pain control in a regular inpatient
care unit setting were safe and not associated with significant
psychotropic effects or hemodynamic side effects that warranted treatment. We do acknowledge that increases in blood
pressure could occur during administration of ketamine;
however, we recorded only instances where changes in blood
pressure warranted treatment with vasoactive drugs. Further,
while there were no records of hallucinations, it is possible
that the presence of hallucinations in young children could
have manifested as dysphoria and those were not recorded.
Nevertheless, ketamine was associated with significant
decreases both in pain scores and opioid intake and these
effects varied according to clinical diagnosis, infusion duration, and pain location.
The greatest reductions in pain scores were observed in
patients with cancer pain and patients with inflammatory
processes including pancreatitis and Crohn’s disease, whereas
patients with functional gastrointestinal disorder, diabetes
mellitus, neurofibromatosis 1, and postural orthostatic
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A

Age group (years, p=0.039)

D

Infusion duration (days, p=0.017)
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Figure 3 Proportion of ketamine infusions associated with a clinically meaningful reduction in pain scores.
Notes: The stacked bars show the proportion of infusions associated with meaningful (≥20% reduction, white bars) and nonmeaningful reductions (<20% reduction, dotted
bars). We defined a clinically meaningful reduction as a ≥20% reduction in pain scores from baseline to the day after ketamine discontinuation. The proportion of infusions
that yielded a meaningful reduction varied according to clinical diagnosis (A, overall effect, p=0.003), pain location (B, p=0.012), age (C, p=0.039), and duration of infusion
(D, p=0.017).
Abbreviations: CA, cancer; IFD, inflammatory disease; SCD, sickle cell disease; POP, postoperative pain; AT, accidental trauma; OT, other; FGID, functional gastrointestinal
disease; UE, upper extremity; Abd, abdominal; Gen, generalized; LE, lower extremity.

tachycardia syndrome had less reduction in pain scores. We
also found that ketamine infusions in patients with cancer
pain, inflammatory diseases, and postoperative pain were
associated with a greater (over 75% of infusions) frequency
of meaningful reduction in pain scores (here defined as a
≥20% reduction). Therefore, this study is informative in
that its findings can be used to help design much-needed
randomized trials to evaluate the effect of ketamine in the
treatment of pain in children, adolescents, and young adults
with poorly controlled pain.
Over the past few years, the use of ketamine for the
treatment of cancer pain has been the focus of significant
debate.15,24,25 The discussion ensued after publication of a
randomized placebo-controlled clinical trial enrolling 185
adult participants with cancer pain, who received ketamine
or placebo delivered subcutaneously.26 That trial showed
that ketamine, administered over 5 days in a dose-escalating
regimen, had no clinical benefit compared to placebo and
was associated with increased adverse events.26 However, researchers argue that the trial used a subcutaneous
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regimen not commonly utilized, the ketamine doses were
escalated rapidly, and the study population was very heterogeneous, all of which are potential limitations of that
trial.25 Therefore, researchers argue that those issues should
tailor the interpretation of the findings26 and those negative
results should not discard the potential role of ketamine
in patients with cancer pain.25 After publication of those
negative results, a survey of clinicians demonstrated that
the practice of using ketamine was continued by 30% of
the respondents24 and the use of ketamine to treat cancer
pain and other types of pain by many specialists has continued.19,24 On balance, one must recognize that the existing
data on the use of ketamine in children with cancer pain
are very limited, most reports consist of small case series,
and randomized clinical trials of ketamine to treat cancer
pain in children are lacking. Nevertheless, we have sided
with those who argue that, while clinical trials are needed,
the practice of using ketamine in children with cancer
pain might be one to be adopted when other options are
unavailable.
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Concerning acute postoperative pain, we found in the
present study that the opioid-sparing effect of ketamine was
minimal. This finding is consistent with our results from a
previous randomized placebo-controlled trial, where ketamine administered in the intraoperative and postoperative
periods did not yield an opioid-sparing effect in adolescents
with scoliosis undergoing spinal fusion.11 Interestingly, a
more recent trial and a new meta-analysis12 also showed lack
of beneficial effect of ketamine in postoperative pain.27 It is
important to note that one limitation of the most recent study
in adolescents undergoing spinal fusion27 as well as ours11 is
that neither study examined the effect of ketamine on chronic
postsurgery pain. Nevertheless, our findings from the present
study are discrepant to those showing that low-dose ketamine
infusion during the perioperative period yields opioid-sparing
effects in adults undergoing major surgeries.28 While we
acknowledge that, in adults, there are data to support the use
of ketamine in the perioperative period, in our institution, we
no longer routinely use ketamine to treat postoperative pain
in our pediatric patients.
One must acknowledge the limitations of this study,
which call for caution in interpreting its results. First, we
report on the use of ketamine in a heterogeneous population
of children, adolescents, and young adults and lack a control group. Further, while there was consistency regarding
the ketamine administration regimen and indications for its
use, timing of administration, and titration of opioids and
ketamine doses were left to the discretion of the pain medicine attending. Additionally, for the purpose of this study,
we regarded ketamine infusions administered to the same
patients as independent infusions and we did not account
for the potential confounding effect of repeated measures by
repeatedly administering ketamine to some patients.

Conclusion
In conclusion, despite its limitations, this study suggests
that in an inpatient setting, the treatment of pain in children,
adolescents, and young adults with subanesthetic doses of
ketamine is feasible and safe in regular patient care units.
The study is also informative in that it suggests that ketamine might have a differential beneficial effect in patients
with certain pain syndromes. Additionally, this study raises
a number of hypotheses to be tested in future clinical trials
to more definitively determine which patients would benefit
from this therapeutic modality. Finally, our findings can be
used to determine sample and effect sizes for future randomized trials to evaluate the role of ketamine for the treatment
of pain in children, adolescents, and young adults.
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